West China Journal of Stomatology ›› 2020, Vol. 38 ›› Issue (4): 449-453.doi: 10.7518/hxkq.2020.04.017

Previous Articles     Next Articles

Development of programmed death receptor-1 and programmed death receptor-1 ligand in oral squamous cell carcinoma

Chen Zhihong1(), Wu Yadong2()   

  1. 1. Dept. of Stomatology, People’s Hospital of Guizhou Province, Guiyang 550002, China
    2. Dept. of Oral and Maxillofacial Surgery, Stomatological Hospital of Guizhou Medical University, Guiyang 550001, China
  • Received:2019-08-21 Revised:2020-04-19 Online:2020-08-01 Published:2020-08-03
  • Contact: Wu Yadong E-mail:wooyadong@163.com


Oral squamous cell carcinoma (OSCC) is a common malignant tumor in the oral and maxillofacial region. At present, the treatment of OSCC is mainly based on surgical oriented comprehensive sequence therapy, especially the triple therapy of surgery, radiotherapy, and chemotherapy. However, the overall five-year survival rate is relatively low. Therefore, researching the pathogenesis and treatment methods of OSCC is important. The immune checkpoint of programmed death receptor-1 (PD-1) and programmed death receptor-1 ligand (PD-L1) have been the focus of research in recent years. Several studies have shown that the high expression of PD-1/PD-L1 in most OSCC microenvironments may contribute to the immune escape of tumors. In this study, the research status of immune checkpoint of PD-1/PD-L1 and its relevant inhibitors in OSCC were reviewed.

Key words: programmed death receptor-1, programmed death receptor-1 ligand, oral squamous cell carcinoma

CLC Number: